XML 49 R36.htm IDEA: XBRL DOCUMENT v3.25.2

Fair Value Disclosures (Tables)

6 Months Ended

May 31, 2025

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis

	May 31, 2025 (1)
$ in thousands	Level 1	Level 2	Level 3	Counterparty and Cash Collateral Netting (2)	Total
Assets:
Financial instruments owned:
Corporate equity securities ..................................................................................	$5,018,987	$417,979	$231,160	$—	$5,668,126
Corporate debt securities .....................................................................................	—	5,375,646	44,682	—	5,420,328
Collateralized debt obligations and collateralized loan obligations ...............	—	685,511	70,948	—	756,459
U.S. government and federal agency securities ................................................	3,139,294	130,185	—	—	3,269,479
Municipal securities ..............................................................................................	—	621,737	—	—	621,737
Sovereign obligations ............................................................................................	694,500	738,064	—	—	1,432,564
Residential mortgage-backed securities ............................................................	—	2,040,529	7,947	—	2,048,476
Commercial mortgage-backed securities ..........................................................	—	72,563	505	—	73,068
Other asset-backed securities .............................................................................	—	579,030	153,681	—	732,711
Loans and other receivables ................................................................................	—	2,572,953	92,168	—	2,665,121
Derivatives ..............................................................................................................	472	3,995,263	8,569	(2,715,818)	1,288,486
Investments at fair value ......................................................................................	—	7	153,379	—	153,386
Total financial instruments owned, excluding Investments at fair value based on NAV ....................................................................................................	$8,853,253	$17,229,467	$763,039	$(2,715,818)	$24,129,941
Securities received as collateral ..........................................................................	$50,968	$—	$—	$—	$50,968
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ..................................................................................	$3,870,700	$14,554	$161	$—	$3,885,415
Corporate debt securities .....................................................................................	—	3,534,470	644	—	3,535,114
Collateralized debt obligations and collateralized loan obligations ...............	—	1	—	—	1
U.S. government and federal agency securities ................................................	2,136,579	5	—	—	2,136,584
Sovereign obligations ............................................................................................	814,027	592,350	—	—	1,406,377
Commercial mortgage-backed securities ..........................................................	—	37	1,153	—	1,190
Loans .......................................................................................................................	—	87,415	313	—	87,728
Derivatives ..............................................................................................................	—	3,768,347	41,857	(3,087,478)	722,726
Total financial instruments sold, not yet purchased .......................................	$6,821,306	$7,997,179	$44,128	$(3,087,478)	$11,775,135
Other secured financings ......................................................................................	$—	$410,413	$18,876	$—	$429,289
Obligation to return securities received as collateral .......................................	50,968	—	—	—	50,968
Long-term debt .......................................................................................................	—	2,313,361	991,156	—	3,304,517

(1)Excludes investments at fair value based on net asset value (“NAV”) of $1.44 billion at May 31, 2025 by level within the fair value hierarchy.

(2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.

	November 30, 2024 (1)
$ in thousands	Level 1	Level 2	Level 3	Counterparty and Cash Collateral Netting (2)	Total
Assets:
Financial instruments owned:
Corporate equity securities ..................................................................................	$5,238,058	$302,051	$239,364	$—	$5,779,473
Corporate debt securities .....................................................................................	—	5,310,815	24,931	—	5,335,746
Collateralized debt obligations and collateralized loan obligations ...............	—	1,029,662	63,976	—	1,093,638
U.S. government and federal agency securities ................................................	3,583,139	160,227	—	—	3,743,366
Municipal securities ..............................................................................................	—	320,507	—	—	320,507
Sovereign obligations ............................................................................................	749,912	630,681	172	—	1,380,765
Residential mortgage-backed securities ............................................................	—	2,348,862	7,714	—	2,356,576
Commercial mortgage-backed securities ..........................................................	—	146,752	477	—	147,229
Other asset-backed securities .............................................................................	—	110,687	103,214	—	213,901
Loans and other receivables ................................................................................	—	1,706,152	152,586	—	1,858,738
Derivatives ..............................................................................................................	146	3,181,454	3,926	(2,667,751)	517,775
Investments at fair value ......................................................................................	—	6	137,865	—	137,871
Total financial instruments owned, excluding Investments at fair value based on NAV ....................................................................................................	$9,571,255	$15,247,856	$734,225	$(2,667,751)	$22,885,585
Securities segregated and on deposit for regulatory purposes or deposited with clearing and depository organizations ................................	$120,414	$—	$—	$—	$120,414
Securities received as collateral ..........................................................................	185,588	—	—	—	185,588
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ..................................................................................	$3,013,877	$73,240	$208	$—	$3,087,325
Corporate debt securities .....................................................................................	—	3,105,010	165	—	3,105,175
U.S. government and federal agency securities ................................................	2,904,379	26	—	—	2,904,405
Sovereign obligations ............................................................................................	667,647	422,124	—	—	1,089,771
Commercial mortgage-backed securities .........................................................	—	—	1,153	—	1,153
Loans .......................................................................................................................	—	92,321	16,864	—	109,185
Derivatives ..............................................................................................................	13	3,477,802	26,212	(2,793,713)	710,314
Total financial instruments sold, not yet purchased .......................................	$6,585,916	$7,170,523	$44,602	$(2,793,713)	$11,007,328
Other secured financings ......................................................................................	$—	$9,964	$14,884	$—	$24,848
Obligation to return securities received as collateral ......................................	185,588	—	—	—	185,588
Long-term debt .......................................................................................................	—	1,529,443	821,903	—	2,351,346

(1)Excludes investments at fair value based on NAV of $1.25 billion at November 30, 2024 by level within the fair value hierarchy.

(2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.

Schedule of Investments Measured at Fair Value Based on Net Asset Value Per Share

Information about our investments in entities that have the

characteristics of an investment company:

	May 31, 2025
$ in thousands	Fair Value (1)	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Hedge Funds (2) ..............	$689,960	$—	Quarterly (50%) Monthly (50%)	45 - 90 days 45 - 60 days
Private Equity Funds (3) ..............	64,532	26,638	N/R (100%)	N/R
Credit Funds (4) ..............	489,597	106	Quarterly (60%) Monthly (2%) N/R (38%)	90 days 30 days N/R
Real Estate and Other Funds (5) ....	196,164	164,982	Quarterly (26%) N/R (74%)	90 days N/R
Total ......................	$1,440,253	$191,726

	November 30, 2024
$ in thousands	Fair Value (1)	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Hedge Funds (2) ............	$660,720	$—	Quarterly (53%) Monthly (47%)	45 - 90 days 45 - 60 days
Private Equity Funds (3) ............	60,215	30,530	N/R (100%)	N/R
Credit Funds (4)	430,429	30,554	Quarterly (72%) Monthly (3%) N/R (25%)	90 days 30 days N/R
Real Estate and Other Funds (5) .	101,325	232,696	N/R (100%)	N/R
Total ...................	$1,252,689	$293,780

N/R - Not redeemable

(1)Where fair value is calculated based on NAV, fair value has been derived from

each of the funds’ capital statements.

(2)Includes investments in hedge funds that invest, long and short, primarily in

both public and private equity securities in domestic and international

markets, commodities and multi-asset securities.

(3)Includes investments in equity funds that invest in the equity of various U.S.

and foreign private companies in a broad range of industries. These

investments cannot be redeemed; instead, distributions are received through

the liquidation of the underlying assets of the funds which are primarily

expected to be liquidated in approximately one to ten years.

(4)Primarily includes investments in funds that invest in:

•distressed and special situations long/short credit strategies across

sectors and asset types;

•short-term trade receivables and payables that are expected to generally

be outstanding between 90 to 120 days;

•distressed and event-driven opportunities across structured credit,

opportunistic credit, and private credit.

(5)Primarily includes investments in corporate real estate strategies focused on

buying or building real estate businesses.

Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis Unobservable Input Reconciliation

Level 3 Rollforwards

	Three Months Ended May 31, 2025
$ in thousands	Balance at February 28, 2025	Total gains/ losses (realized and unrealized) (1)	Purchases	Sales	Settlements	Issuances	Net transfers into/ (out of) Level 3	Balance at May 31, 2025	For instruments still held at May 31, 2025, changes in  unrealized gains (losses) included in:
									Earnings (1)	Other comprehensive income (loss) (1)
Level 3 assets:
Financial instruments owned:
Corporate equity securities ....................	$212,409	$8,245	$2,482	$(2,201)	$—	$—	$10,225	$231,160	$5,003	$—
Corporate debt securities ......................	25,925	2,547	18,805	(15,740)	(2,177)	—	15,322	44,682	2,194	—
CDOs and CLOs .......................................	71,827	(4,123)	35,644	(18,469)	(6,550)	—	(7,381)	70,948	(4,564)	—
RMBS ........................................................	7,526	436	—	—	(15)	—	—	7,947	439	—
CMBS ........................................................	471	34	—	—	—	—	—	505	34	—
Other ABS .................................................	147,319	6,814	27,523	(26,231)	(1,863)	—	119	153,681	5,985	—
Loans and other receivables .................	153,764	(7,236)	18,008	(39,475)	(13,063)	—	(19,830)	92,168	(10,875)	—
Investments at fair value ........................	157,881	6,041	261	—	(804)	—	(10,000)	153,379	3,581	—
Level 3 liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ....................	$590	$(256)	$(173)	$—	$—	$—	$—	$161	$31	$—
Corporate debt securities ......................	1,113	222	(41,346)	41,436	(662)	—	(119)	644	(86)	—
RMBS ........................................................	15	(15)	—	—	—	—	—	—	—	—
CMBS ........................................................	1,154	(1)	—	35	—	—	(35)	1,153	1	—
Loans ........................................................	848	(658)	(37)	—	183	—	(23)	313	(226)	—
Net derivatives (2) ...................................	42,076	(1,132)	—	—	(4)	—	(7,652)	33,288	(6,385)	—
Other secured financings .......................	12,705	—	—	—	(2,360)	8,531	—	18,876	—	—
Long-term debt ........................................	860,684	34,729	—	—	(5,893)	93,570	8,066	991,156	(49,509)	14,781

	Six Months Ended May 31, 2025
$ in thousands	Balance at November 30, 2024	Total gains/ losses (realized and unrealized) (1)	Purchases	Sales	Settlements	Issuances	Net transfers into/ (out of) Level 3	Balance at May 31, 2025	For instruments still held at May 31, 2025, changes in  unrealized gains (losses) included in:
									Earnings (1)	Other comprehensive income (loss) (1)
Assets:
Financial instruments owned:
Corporate equity securities ................	$239,364	$9,940	$7,049	$(5,366)	$494	$—	$(20,321)	$231,160	$8,292	$—
Corporate debt securities ...................	24,931	2,147	37,129	(23,787)	(2,197)	—	6,459	44,682	2,419	—
CDOs and CLOs ...................................	63,976	(10,286)	52,875	(23,728)	(6,550)	—	(5,339)	70,948	(10,336)	—
Sovereign obligations .........................	172	2	—	(174)	—	—	—	—	—	—
RMBS .....................................................	7,714	269	—	—	(36)	—	—	7,947	279	—
CMBS ....................................................	477	28	—	—	—	—	—	505	28	—
Other ABS .............................................	103,214	(264)	86,866	(30,929)	(4,175)	—	(1,031)	153,681	(565)	—
Loans and other receivables ..............	152,586	(5,759)	72,851	(82,603)	(21,549)	3,670	(27,028)	92,168	(9,134)	—
Investments at fair value ....................	137,865	6,434	21,549	—	(2,469)	—	(10,000)	153,379	3,974	—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities ................	$208	$126	$(173)	$—	$—	$—	$—	$161	$(126)	$—
Corporate debt securities ...................	165	52	(135,198)	135,433	—	—	192	644	(123)	—
CMBS ....................................................	1,153	—	—	35	—	—	(35)	1,153	—	—
Loans ....................................................	16,864	(1,673)	(1,046)	—	698	—	(14,530)	313	39	—
Net derivatives (2) ...............................	22,286	(13,925)	—	22,588	(484)	—	2,823	33,288	5,076	—
Other secured financings ...................	14,884	241	—	—	(4,780)	8,531	—	18,876	(241)	—
Long-term debt ....................................	821,903	(21,118)	—	—	(2,799)	218,124	(24,954)	991,156	(19,522)	40,640

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes

within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

	Three Months Ended May 31, 2024
$ in thousands	Balance at February 28, 2024	Total gains/ losses (realized and unrealized) (1)	Purchases	Sales	Settlements	Issuances	Net transfers into/ (out of) Level 3	Balance at May 31, 2024	For instruments still held at May 31, 2024, changes in unrealized gains (losses) included in:
									Earnings (1)	Other comprehensive income (loss) (1)
Assets:
Financial instruments owned:
Corporate equity securities .................	$173,214	$(12,751)	$15,398	$(18)	$—	$—	$2,912	$178,755	$(12,404)	$—
Corporate debt securities ...................	35,335	1,363	1,091	(16,250)	—	—	17,178	38,717	89	—
CDOs and CLOs ....................................	69,367	1,220	6,810	(1,905)	(5,527)	—	(1,339)	68,626	(675)	—
RMBS .....................................................	684	(6)	—	—	(34)	—	—	644	—	—
CMBS .....................................................	473	4	—	—	—	—	—	477	—	—
Other ABS ..............................................	102,256	(2,198)	63,554	(15,138)	(35,363)	—	55,625	168,736	(1,694)	—
Loans and other receivables ..............	78,885	1,255	11,329	(4,161)	(35)	—	5,273	92,546	579	—
Investments at fair value .....................	121,764	1,616	15,224	(547)	—	—	—	138,057	1,616	—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities .................	675	8	—	25	—	—	—	708	(8)	—
Corporate debt securities ...................	124	(23)	—	246	—	—	159	506	23	—
CMBS .....................................................	944	—	—	—	105	—	—	1,049	—	—
Loans .....................................................	1,466	(251)	(925)	2,801	81	—	(1,588)	1,584	309	—
Net derivatives (2) ................................	52,089	(10,062)	—	—	(9,689)	—	2,539	34,877	(178)	—
Other secured financings ....................	3,965	—	—	—	—	—	—	3,965	—	—
Long-term debt .....................................	779,529	(2,477)	—	—	(2,109)	6,616	2,653	784,212	9,334	(6,857)

	Six Months Ended May 31, 2024
$ in thousands	Balance at November 30, 2023	Total gains/ losses (realized and unrealized) (1)	Purchases	Sales	Settlements	Issuances	Net transfers into/ (out of) Level 3	Balance at May 31, 2024	For instruments still held at May 31, 2024, changes in unrealized gains (losses) included in:
									Earnings (1)	Other comprehensive income (loss) (1)
Assets:
Financial instruments owned:
Corporate equity securities ................	$181,294	$(12,817)	$15,956	$(2,230)	$—	$—	$(3,448)	$178,755	$(12,175)	$—
Corporate debt securities ...................	26,112	3,830	25,563	(17,217)	(200)	—	629	38,717	2,997	—
CDOs and CLOs ...................................	64,862	9,006	20,333	(15,838)	(7,293)	—	(2,444)	68,626	4,904	—
RMBS .....................................................	20,871	(207)	32	(32)	(5,395)	—	(14,625)	644	33	—
CMBS ....................................................	508	(35)	4	—	—	—	—	477	(64)	—
Other ABS .............................................	117,661	(5,913)	76,263	(32,817)	(26,619)	—	40,161	168,736	(3,938)	—
Loans and other receivables ..............	130,101	(39,831)	18,555	(3,974)	(17,892)	—	5,587	92,546	(17,220)	—
Investments at fair value ....................	130,835	(9,079)	16,855	—	(547)	—	(7)	138,057	(9,079)	—
Liabilities:
Financial instruments sold, not yet purchased:
Corporate equity securities	$676	$1	$—	$31	$—	$—	$—	$708	$(1)	$—
Corporate debt securities ...................	124	(23)	—	246	—	—	159	506	23	—
CMBS ....................................................	840	—	(245)	—	455	—	(1)	1,049	—	—
Loans ....................................................	1,521	(114)	(1,041)	3,642	114	—	(2,538)	1,584	107	—
Net derivatives (2) ...............................	50,955	(17,979)	(978)	2,913	(9,486)	—	9,452	34,877	9,057	—
Other secured financings ...................	3,898	4,482	—	—	(4,415)	—	—	3,965	(4,482)	—
Long-term debt ....................................	744,597	9,651	—	—	(2,109)	28,072	4,001	784,212	(5,117)	(4,534)

(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes

within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income.

(2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.

Schedule of Fair Value Inputs Assets and Liabilities Quantitative Information Table

May 31, 2025
Financial Instruments Owned	Fair Value (in thousands)	Valuation Technique	Significant Unobservable Input(s)	Input / Range			Weighted Average
Corporate equity securities .....................	$205,389
Non-exchange-traded securities		Market approach	Price	$0	-	$486	$80
Corporate debt securities ........................	$38,700	Market approach	Price	$49	-	$118	$52
		Discounted cash flows	Discount rate/yield	18%	-	26%	21%
CDOs and CLOs ..........................................	$63,639	Discounted cash flows	Constant prepayment rate	20%			—
			Constant default rate	2%			—
			Loss severity	30%			—
			Discount rate/yield	13%	-	19%	17%
		Market approach	Price	$98	-	$114	$105
RMBS ...........................................................	$7,947	Discounted cash flows	Constant prepayment rate	40%			—
			Loss severity	90%			—
			Discount rate/yield	18%			—
Other ABS ...................................................	$152,664	Discounted cash flows	Discount rate/yield	10%	-	29%	19%
			Cumulative loss rate	11%	-	34%	17%
			Duration (years)	0.6	-	1.2	1.0
		Market approach	Price	$114	-	$135	$122
		Scenario analysis	Estimated recovery percentage	83%			—
Loans and other receivables ...................	$92,168	Market approach	Price	$8	-	$114	$92
		Scenario analysis	Estimated recovery percentage	17%	-	251%	91%
Derivatives ..................................................	$4,701
Embedded options		Market approach	Basis points upfront	0.3			—
Investments at fair value ..........................	$148,059
Private equity securities		Market approach	Price	$0	-	$9,133	$1,704
			Discount rate/yield	28%			—
			Estimated revenue	$29,733,947			—
Financial Instruments Sold, Not Yet Purchased:
Derivatives ..................................................	$40,701
Equity options		Volatility benchmarking	Volatility	49%	-	51%	50%
Options		Market approach	Basis points upfront	0.0	-	23.8	15.6
Other secured financings .........................	$18,876	Scenario analysis	Estimated recovery percentage	76%	-	100%	96%
		Market approach	Price	$112	-	$117	$114
Long-term debt ..........................................	$990,274
Structured notes		Market approach	Price	$66	-	$116	$97

November 30, 2024
Financial Instruments Owned	Fair Value (in thousands)	Valuation Technique	Significant Unobservable Input(s)	Input / Range			Weighted Average
Corporate equity securities .....................	$239,364
Non-exchange-traded securities		Market approach	Price	$0	-	$486	$68
Corporate debt securities ........................	$24,931	Market approach	Price	$28	-	$105	$74
CDOs and CLOs ..........................................	$53,388	Discounted cash flows	Constant prepayment rate	20%			—
			Constant default rate	2%			—
			Loss severity	30%			—
			Discount rate/yield	14%	-	32%	26%
		Market approach	Price	$70	-	$106	$94
RMBS ...........................................................	$7,714	Discounted cash flows	Constant prepayment rate	20%			—
			Loss severity	10%			—
			Discount rate/yield	12%			—
Other ABS ...................................................	$98,172	Discounted cash flows	Discount rate/yield	19%	-	30%	25%
			Cumulative loss rate	17%	-	34%	24%
			Duration (years)	0.9	-	1.0	0.9
		Market approach	Price	$106	-	$127	$121
		Scenario analysis	Estimated recovery percentage	92%			—
Loans and other receivables ...................	$152,586	Market approach	Price	$17	-	$106	$75
		Scenario analysis	Estimated recovery percentage	3%	-	252%	50%
Derivatives ..................................................	$1,396
Embedded options		Market approach	Basis points upfront	0.3			—
Investments at fair value ..........................	$132,769
Private equity securities		Market approach	Price	$1	-	$8,506	$501
			Discount rate/yield	28%			—
			Estimated revenue	$29,908,372			—
Financial Instruments Sold, Not Yet Purchased:
Loans ..........................................................	$16,864	Market approach	Price	$17	-	$100	$75
		Scenario analysis	Estimated recovery percentage	0%	-	205%	50%
Derivatives ..................................................	$25,045
Equity options		Volatility benchmarking	Volatility	28%	-	102%	49%
Options		Market approach	Basis points upfront	8.0	-	22.3	14.9
Other secured financings .........................	$14,884	Scenario analysis	Estimated recovery percentage	60%	-	100%	93%
		Market approach	Price	$117			—
Long-term debt ..........................................	$821,903
Structured notes		Market approach	Price	$61	-	$122	$96

Schedule of Fair Value Option Gains (Losses) and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables

Fair value option gains (losses):

	Three Months Ended  May 31,		Six Months Ended  May 31,
$ in thousands	2025	2024	2025	2024
Financial instruments owned:
Loans and other receivables (1) .	$69,578	$(28,264)	$103,854	$(39,691)
Other secured financings:
Other changes in fair value (1) ...	$(1,418)	$—	$(1,659)	$(4,482)
Long-term debt:
Changes in instrument-specific credit risk (2) ............................	$28,763	$(13,790)	$66,501	$(17,769)
Other changes in fair value (1) ...	13,225	16,367	27,548	(27,451)

(1)Other changes in fair value are included in Principal transactions revenues.

(2)Changes in fair value of structured notes related to instrument-specific credit

risk are presented net of tax in our Consolidated Statements of

Comprehensive Income.

Fair value option amounts by which contractual principal is

greater than (less than) fair value:

$ in thousands	May 31,  2025	November 30, 2024
Financial instruments owned:
Loans and other receivables (1) ...............................	$1,635,461	$1,603,512
Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2) ...............................................................	135,253	132,838
Long-term debt ...........................................................	266,641	131,107
Other secured financings .........................................	(1,200)	459

(1)Interest income is recognized separately from other changes in fair value and

is included in Interest revenues.

(2)Amounts include loans and other receivables 90 days or greater past due by

which contractual principal exceeds fair value of $50.3 million and $48.8

million at May 31, 2025 and November 30, 2024, respectively.

X

- Definition

Reconciliation of beginning Level 3 assets and liabilities to ending Level 3 assets and liabilities (specifically disaggregating purchases, sales, settlements, issuances, transfers to Level 3 and transfers out of Level 3).

+ References

No definition available.

+ Details

Name:	jef_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTableTextBlock
Namespace Prefix:	jef_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of quantitative information about significant unobservable inputs used in the fair value measurement of Level 3 financial assets and liabilities, including valuation technique and range of inputs

+ References

No definition available.

+ Details

Name:	jef_FairValueInputsAssetsAndLiabilitiesQuantitativeInformationTableTableTextBlock
Namespace Prefix:	jef_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_FairValueDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 54B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482134/820-10-35-54B

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

+ Details

Name:	us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information about asset and liability measured at fair value under fair value option.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-SubTopic 10
-Topic 825
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-12

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

+ Details

Name:	us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration